Kenvue (US:KVUE) ZACKSยท2024-08-06 14:36Core Insights - Kenvue reported $4 billion in revenue for the quarter ended June 2024, reflecting a year-over-year decline of 0.3% and an EPS of $0.32, unchanged from the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $3.93 billion by 1.75%, while the EPS surpassed the consensus estimate of $0.28 by 14.29% [1] Revenue Performance - Net Sales in Self Care reached $1.64 billion, matching the average estimate from three analysts [3] - Net Sales in Essential Health amounted to $1.26 billion, slightly above the average estimate of $1.23 billion from three analysts [4] - Net Sales in Skin Health and Beauty totaled $1.10 billion, slightly below the average estimate of $1.11 billion from three analysts [5] Adjusted Operating Income - Adjusted Operating Income for Self Care was $534 million, below the average estimate of $558.98 million from two analysts [6] - Adjusted Operating Income for Essential Health was $359 million, significantly above the average estimate of $154.69 million from two analysts [7] - Adjusted Operating Income for Skin Health and Beauty was $165 million, below the average estimate of $195.87 million from two analysts [8] Stock Performance - Kenvue shares have returned -0.3% over the past month, compared to a -6.7% change in the Zacks S&P 500 composite [8] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [8]